{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002220","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.828505+00:00","generated_at":"2026-06-03T08:07:30.472084+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA grants Fast Track Designation for Compass's CTX-009 in biliary tract cancer","bullets":["FDA Fast Track Designation for CTX-009 (bispecific DLL4/VEGF-A antibody) + paclitaxel in previously treated metastatic/locally advanced biliary tract cancer.","Phase 2 data showed ORR 37.5% (9/24), median PFS 9.4 months, median OS 12.5 months.","Enrollment in Phase 2/3 COMPANION-002 study expected to complete mid-2024; top-line data by year-end 2024.","Co-founder Thomas Schuetz highlighted large unmet need with current single-digit response rates."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002220","json":"https://secwatch.observer/filing/0001171843-24-002220.json","markdown":"https://secwatch.observer/filing/0001171843-24-002220.md","text":"https://secwatch.observer/filing/0001171843-24-002220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/0001171843-24-002220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/f8k_042424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:07:30.472084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}